![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
AstraZeneca |
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00612404 |
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. gastroenterologists) are asked to document relevant data in patients with gastrointestinal disorders.
Condition |
Gastrointestinal Diseases |
MedlinePlus related topics: | Endoscopy |
Drug Information available for: | Esomeprazole magnesium Esomeprazole Sodium Omeprazole Omeprazole magnesium |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Symptoms and Endoscopic Results in Consideration of Pretreatment |
Enrollment: | 16255 |
Study Start Date: | September 2005 |
Primary Completion Date: | December 2005 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
1
patients with gastrointestinal disorders who need an endoscopy.
|
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
gastroenterologists; specialists
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | AstraZeneca Germany ( Dr Kai Richter ) |
Study ID Numbers: | 1312004008 |
First Received: | January 28, 2008 |
Last Updated: | February 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00612404 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
|
![]() |